Officer Andrew Callos Files Intent to Sell $5.28M in Shares
CYTK has more than doubled off its 52-week low of $29.31.
Summary
An officer at Cytokinetics has filed a Form 144 to sell $5.28 million in company stock, continuing a recent trend of insider dispositions.
Key Events · Ownership and Investor Activity · CYTK
-
Officer Files Intent to Sell Shares
Andrew Callos, an officer, filed a Form 144 to sell 79,639 shares of common stock, valued at approximately $5.28 million.
-
Shares from Option Exercise and RSUs
The shares to be sold were acquired through the exercise of stock options (72,190 shares) and vesting of restricted stock units (7,449 shares).
-
Continuation of Insider Selling Pattern
This filing is part of an ongoing pattern of insider selling by Mr. Callos, with over $3.79 million in shares already sold in the past three months, some under 10b5-1 plans.
Analysis · CYTK · Life Sciences
Andrew Callos, an officer at Cytokinetics, has filed a Form 144 indicating his intent to sell approximately $5.28 million worth of common stock. This proposed sale follows a pattern of insider selling from Mr. Callos, including previous sales under 10b5-1 plans. The shares intended for sale are primarily derived from the exercise of stock options and vesting of restricted stock units. While these sales are often for liquidity or tax planning, a consistent pattern of officer selling can be viewed negatively by the market, especially given the company's recent commercial launch plans for MYQORZO.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYTK was trading at $64.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $29.31 to $70.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.